Company intelligence / Profile preview

Adastra Pharmaceuticals

Princeton, New Jersey, United Statesbio.org ↗

Ownership: Private
Development stage: Preclinical

Overview

Adastra Pharmaceuticals developed small molecule therapies targeting aggressive cancers, notably high-grade gliomas. Its lead program was zotiraciclib, a multi-CDK inhibitor that reached Phase 2 clinical trials before being acquired by Cothera Bioscience in 2021. The company is no longer independently developing assets.

Therapeutic areas: Oncology
Modalities: Small molecules
Industry: Biotech

Partnerships

European Organisation for Research and Treatment of Cancer (EORTC) as a collaborator on clinical trials.

Beyond the preview

Go deeper on Adastra Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Adastra Pharmaceuticals.

Explore the full profile